<DOC>
	<DOCNO>NCT00239343</DOCNO>
	<brief_summary>The aim study estimate effect preoperative gefitinib complete pathological response rate primary estrogen receptor negative breast cancer time surgery .</brief_summary>
	<brief_title>Phase II Trial Preoperative Therapy With Gefitinib Chemotherapy Patients With ERneg Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>histologically confirm oestrogen receptor negative primary breast cancer , tumour stage T23 , N02 , M0 . Eligible surgery , WHO performance score 01. prior anticancer therapy include gefitinib ( Iressa® ) , epirubicin ( Farmorubicin™ ) , cyclophosphamide , distant metastasis bilateral breast cancer , evidence clinically active interstitial lung disease , coexist malignancy malignancy diagnose within last 5 year exception basal cell carcinoma cervical cancer situ , pregnancy breastfeeding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>